Skip to main content

Table 2 Characteristics of hereditary cancer syndromes by population prevalence, proband's health status and frequency of index cancers among blood relatives.

From: Population screening for hereditary and familial cancer syndromes in Valka district of Latvia

Diagnosis

Population prevalence

Affected probands

Cancer frequency

 

Value,%

95% CI,%

Fr,%

95% CI,%

Value,%

95% CI,%

HNPCC/g1

0.06

0.03 - 0.10

18.2

5.1 - 47.7

30.1

23.3 - 38.0

     

15.8CRC

10.7 - 22.5CRC

     

22.4EF

14.8 - 32.3EF

HNPCC/g2

0.11

0.07 - 0.17

5

0.9 - 23.6

15.5

11.6 - 20.3

     

10.6CRC

7.4 - 14.8CRC

     

9.6EF

5.7 - 15.8EF

HNPCC/g3

0.17

0.12 - 0.24

9.7

3.3 - 24.9

19.3

16.5 - 22.5

     

12.4CRC

9.6 - 15.9CRC

     

14.5EF

10.5 - 19.8EF

FCC/g2

0.11

0.07 - 0.17

5

0.9 - 23.6

17.0

12.8 - 22.3

HB+OC/g1

0.03

0.01 - 0.06

20

3.6 - 62.4

24.6 F

15.5 - 36.7 F

HBC1/g2

0.63

0.52 - 0.75

4.3

1.8 - 9.6

8.6

7.2 - 10.2

     

16.3F

13.8 - 19.1F

HBC2/g2

0.34

0.27 - 0.44

18.8

11.1 - 30.0

31.8F

27.5 - 36.4F

HBOC1/g2

0.03

0.02 - 0.07

0

0 - 39.0

19.3F

9.2 - 36.3 F

HBOC2/g2

0.16

0.11 - 0.22

20.7

9.8 - 38.4

30.8F

25.0 - 37.3F

HOC/g2

0.008

0.001 - 0.06

0

0 - 49.0

36.4F

19.7 - 57.0F

HB+OC/g2

1.18

1.04 - 1.35

10.5

7.1 - 15.2

12.6 F

11.4 - 13.9 F

     

23.6F

21.4 - 25.9F

HEC/g1

0.03

0.01 - 0.06

0

0 - 43.3

41.5F

27.8 - 56.6F

HEC/g2

0.14

0.10 - 0.20

15.4

6.2 - 33.5

32.2F

25.7 - 39.4 F

FEC/g1

0.01

0.003 - 0.04

0

0 - 65.8

46.2 F

23.2 - 70.9 F

FEC1/g2

0.13

0.09 - 0.19

12.5

4.3 - 31.0

28.7 F

22.4 - 36.0 F

FEC2/g2

0.05

0.03 - 0.09

11.1

2.0 - 43.5

32.4 F

22.4 - 44.2 F

H+FEC/g1

0.04

0.02 - 0.08

0

0 - 35.4

42.6 F

36.3 - 55.8 F

H+FEC/g2

0.32

0.25 - 0.41

13.6

7.0 - 24.5

30.8 F

26.5 - 35.4 F

H+FEC g3

0.35

0.28 - 0.45

14.3

7.4 - 25.7

41.0 F

36.1 - 46.2 F

HGC/g1

0.11

0.07 - 0.17

4.8

0.8 - 22.7

25.2

20.6 - 30.4

HGC/g2

0.40

0.32 - 0.50

0

0 - 4.9

16.0

13.8 - 18.5

HGC/g3

0.51

0.42 - 0.62

1.1

0.2 - 5.7

18.2

16.2 - 20.5

FLC/g1

0.07

0.04 - 0.12

0

0 - 22.8

25.5

19.3 - 32.8

FLC/g2

0.50

0.41 - 0.61

0

0 - 4.0

17.2

15.0 - 19.7

FLC/g3

0.57

0.47 - 0.69

0

0 - 3.5

18.3

16.2 - 20.7

HPC/g1

0.005

0.001 - 0.03

100

20.7 - 100

21.4M

7.6 - 47.6M

HPC/g2

0.11

0.07 - 0.17

19.0

7.7 - 40.0

22.2M

16.4 - 29.4M

HPC/g3

0.12

0.08 - 0.18

22.7

10.1 - 43.4

22.2

16.5 - 29.0

FPanC/g1

0.05

0.03 - 0.10

10

1.8 - 40.4

14.7

9.1 - 22.9

FBlaC/g1

0.01

0.003 - 0.04

0

0 - 65.8

31.6

15.4 - 54.0

FBlaC/g2

0.05

0.03 - 0.09

0

0 - 29.9

20.0

11.8 - 31.8

FBlaC/g3

0.06

0.03 - 0.11

0

0 - 25.9

22.8

14.9 - 33.2

FHemT/g1

0.005

0.001 - 0.03

0

0 - 79.3

30.8

12.7 - 57.6

FHemT/g2

0.09

0.05 - 0.14

6.3

1.1 - 28.3

15.4

11.2 - 20.9

FHemT/g3

0.09

0.06 - 0.15

5.9

1.0 - 27.0

16.3

12.1 - 21.2

FBT/g1

0.02

0.005 - 0.05

0

0 - 56.2

32.3

18.6 - 49.9

FBT/g2

0.09

0.05 - 0.14

0

0 - 19.4

14.4

10.4 - 19.5

FBT/g3

0.10

0.07 - 0.16

0

0 - 16.8

16.5

12.5 - 21.5

  1. CRC colorectal cancer; EF endometrial cancer in female; F in female; M in male
  2. CI, confidence interval; Fr, frequency; HB+OC, combined group of hereditary breast and/or ovarian cancer; H+FEC, combined group of hereditary and familial endometrial cancer